Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ranica – page 139

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ranica at a glance
2 668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 668 trials in Ranica

Open in trial search

Acute myocardial infarction+1

Not recruiting

Study on the Effects of Warfarin, Lysine Aspirin, and Clopidogrel in Patients with Myocardial Infarction and Non-Obstructive Coronary Arteries (MINOCA)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Cholangiocarcinoma

Not recruiting

Study on Pre-Surgery Treatment for Locally Advanced Cholangiocarcinoma Using Durvalumab, Tremelimumab, Cisplatin, and Gemcitabine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Chemotherapy cardiotoxicity attenuation

Not recruiting

Study on Dapagliflozin to Reduce Heart Damage from Chemotherapy in Breast Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione IRCCS Policlinico San Matteo

Colorectal cancer metastatic

Not recruiting

Study on Cetuximab-Based Treatment for Metastatic Colorectal Cancer in Patients with RAS/BRAF Wild Type Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemo-Immunotherapy for Patients with Stage III Unresectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione IRCCS Policlinico San Matteo

Ovarian cancer

Not recruiting

Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Pancreatic carcinoma metastatic

Not recruiting

Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Alemtuzumab
  • Sponsor:Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S

Asthma

Not recruiting

Study on the Safety and Effectiveness of AZD8630 for Adults with Uncontrolled Asthma at Risk of Exacerbations

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin
  • Sponsor:AstraZeneca AB

Cushing's syndrome

Not recruiting

Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Corcept Therapeutics Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Kaposi's sarcoma

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Classic Kaposi Sarcoma After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

  • IC-MPGN Treatment Evaluation
  • C3 Glomerulopathy Research
  • Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

  • Primary Membranous Nephropathy
  • IgA Nephropathy Interventions
  • Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

  • Disease Progression Prevention
  • Hyperkalemia Management
  • Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.